Nkarta, Inc. (NKTX) stock declined over -6.34%, trading at $1.92 on NASDAQ, down from the previous close of $2.05. The stock opened at $2.02, fluctuating between $1.91 and $2.07 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 05, 2026 | 2.03 | 2.07 | 1.91 | 1.92 | 1.06M |
| Feb 04, 2026 | 2.23 | 2.24 | 2.02 | 2.05 | 556.83K |
| Feb 03, 2026 | 2.19 | 2.27 | 2.16 | 2.22 | 745.54K |
| Feb 02, 2026 | 2.20 | 2.25 | 2.12 | 2.16 | 1.06M |
| Jan 30, 2026 | 2.36 | 2.42 | 2.19 | 2.22 | 1.45M |
| Jan 29, 2026 | 2.45 | 2.47 | 2.38 | 2.43 | 493.44K |
| Jan 28, 2026 | 2.54 | 2.55 | 2.43 | 2.47 | 469.3K |
| Jan 27, 2026 | 2.47 | 2.56 | 2.44 | 2.54 | 688.06K |
| Jan 26, 2026 | 2.49 | 2.55 | 2.40 | 2.46 | 755.26K |
| Jan 23, 2026 | 2.46 | 2.60 | 2.40 | 2.49 | 1.77M |
| Jan 22, 2026 | 2.20 | 2.40 | 2.17 | 2.40 | 1.64M |
| Jan 21, 2026 | 2.02 | 2.20 | 2.01 | 2.20 | 1.04M |
| Jan 20, 2026 | 2.00 | 2.06 | 1.99 | 2.04 | 357.09K |
| Jan 16, 2026 | 1.96 | 2.06 | 1.93 | 2.04 | 962.47K |
| Jan 15, 2026 | 2.07 | 2.07 | 1.96 | 1.96 | 955.29K |
| Jan 14, 2026 | 2.05 | 2.10 | 2.04 | 2.07 | 545.53K |
| Jan 13, 2026 | 2.17 | 2.18 | 2.05 | 2.05 | 790.65K |
| Jan 12, 2026 | 2.10 | 2.19 | 2.04 | 2.18 | 794.23K |
| Jan 09, 2026 | 2.12 | 2.14 | 2.04 | 2.09 | 720.99K |
| Jan 08, 2026 | 2.03 | 2.21 | 2.00 | 2.11 | 1.58M |
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| Employees | 157 |
| Beta | 0.61 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep